MiNK Therapeutics, Inc. (NASDAQ:INKT) Given Average Rating of “Hold” by Brokerages

MiNK Therapeutics, Inc. (NASDAQ:INKT) has received an average rating of “Hold” from the five brokerages that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, one has assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $35.00.

A number of brokerages have issued reports on INKT. Wall Street Zen upgraded MiNK Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, January 19th. Zacks Research upgraded MiNK Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, October 20th.

Institutional Trading of MiNK Therapeutics

An institutional investor recently bought a new position in MiNK Therapeutics stock. DRW Securities LLC acquired a new position in MiNK Therapeutics, Inc. (NASDAQ:INKT) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 25,677 shares of the company’s stock, valued at approximately $286,000. DRW Securities LLC owned about 0.55% of MiNK Therapeutics at the end of the most recent reporting period. 2.87% of the stock is owned by hedge funds and other institutional investors.

MiNK Therapeutics Stock Up 2.1%

INKT stock opened at $11.28 on Friday. MiNK Therapeutics has a 52 week low of $6.34 and a 52 week high of $76.00. The firm has a market capitalization of $52.88 million, a P/E ratio of -3.72 and a beta of 0.34. The company has a fifty day simple moving average of $11.88 and a two-hundred day simple moving average of $13.19.

MiNK Therapeutics (NASDAQ:INKT) last announced its earnings results on Friday, November 14th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.86) by $0.21. As a group, analysts anticipate that MiNK Therapeutics will post -2.75 EPS for the current year.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.